Repurposing licensed drugs can be an affordable and effective way to bring new treatments to market, but initial efforts tend to lack funding from big pharma. In Vivo takes a closer look at repurposing projects across the central nervous system space, what it is that drives the work forward and how innovative trial design is changing the game.
Highly anticipated results from the US National Institutes of Health’s Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) initiative proved disappointing for the research community in October last year, as the study revealed that sildenafil and tadalafil were not suitable candidates for treating dementia.
NIH researchers examined the risk of Alzheimer’s and related dementias using two groups of Medicare beneficiaries with pulmonary atrial hypertension;...
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
